Compare BLLN & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | FOLD |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.4B |
| IPO Year | 2025 | 2007 |
| Metric | BLLN | FOLD |
|---|---|---|
| Price | $92.70 | $14.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $137.83 | $26.11 |
| AVG Volume (30 Days) | 222.9K | ★ 8.1M |
| Earning Date | 12-09-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $254,136,000.00 | ★ $598,704,000.00 |
| Revenue This Year | $98.01 | $21.49 |
| Revenue Next Year | $36.76 | $18.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 254.30 | 21.28 |
| 52 Week Low | $80.00 | $5.51 |
| 52 Week High | $138.70 | $14.38 |
| Indicator | BLLN | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 78.81 |
| Support Level | $80.65 | $14.30 |
| Resistance Level | $87.54 | $14.31 |
| Average True Range (ATR) | 5.60 | 0.03 |
| MACD | 0.97 | -0.12 |
| Stochastic Oscillator | 88.21 | 35.00 |
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.